肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
Cancer Research and Clinic
2015年
10期
711-713
,共3页
肺肿瘤%细胞程序性死亡受体-1%细胞程序性死亡配体-1%表皮生长因子受体%免疫疗法
肺腫瘤%細胞程序性死亡受體-1%細胞程序性死亡配體-1%錶皮生長因子受體%免疫療法
폐종류%세포정서성사망수체-1%세포정서성사망배체-1%표피생장인자수체%면역요법
Carcinoma,non-small-cell lung%Programmed death-1%Programmed death ligand-1%Epithelial growth factor receptor%Immunotherapy
肺癌是导致人类癌性死亡的首要疾病.细胞程序性死亡受体-1(PD-1)是CD28分子家族的成员之一,表达于多种免疫细胞表面,细胞程序性死亡配体-1(PD-L1)为其配体之一,可分为膜型和可溶型两种形式,在肿瘤免疫逃逸机制中扮演着重要的角色.最近有研究显示,非小细胞肺癌(NSCLC)细胞中经突变的表皮生长因子受体(EGFR)基因可直接上调肿瘤细胞的PD-L1表达.文章就PD-1、PD-L1及EGFR基因突变在NSCLC免疫治疗中的临床意义进行综述.
肺癌是導緻人類癌性死亡的首要疾病.細胞程序性死亡受體-1(PD-1)是CD28分子傢族的成員之一,錶達于多種免疫細胞錶麵,細胞程序性死亡配體-1(PD-L1)為其配體之一,可分為膜型和可溶型兩種形式,在腫瘤免疫逃逸機製中扮縯著重要的角色.最近有研究顯示,非小細胞肺癌(NSCLC)細胞中經突變的錶皮生長因子受體(EGFR)基因可直接上調腫瘤細胞的PD-L1錶達.文章就PD-1、PD-L1及EGFR基因突變在NSCLC免疫治療中的臨床意義進行綜述.
폐암시도치인유암성사망적수요질병.세포정서성사망수체-1(PD-1)시CD28분자가족적성원지일,표체우다충면역세포표면,세포정서성사망배체-1(PD-L1)위기배체지일,가분위막형화가용형량충형식,재종류면역도일궤제중분연착중요적각색.최근유연구현시,비소세포폐암(NSCLC)세포중경돌변적표피생장인자수체(EGFR)기인가직접상조종류세포적PD-L1표체.문장취PD-1、PD-L1급EGFR기인돌변재NSCLC면역치료중적림상의의진행종술.
Lung cancer is the leading cause of cancer-related death in the world.PD-1 is a member of the CD28 family expressed on the surface of a variety of immune cells.PD-L1, one of PD-1 ligands, plays a pivotal role in the ability of tumor cells to evade the host immune system.A recent study showed that signaling via mutant EGFR in lung tumor cells upregulates directly tumor PD-L1 expression.In this review, the clinical significance of the PD-1/PD-L1 pathway in immunotherapy for non-small-cell lung cancer (NSCLC) and the relevance to targeted therapy were summarized.
